Profound Medical was honored with the 2025/2026 Mount Logan Award in recognition of its consistent project milestone achievements, international acclaim, and leadership in image-guided therapy. This accolade highlights the company’s standing as a Canadian innovator in interventional MRI procedures and reinforces its credibility within the medical technology industry.

Over the past year, Profound treated its 4,000th patient using the TULSA Procedure and secured new U.S. Medicare reimbursement codes, enhancing revenue potential for prostate disease treatments. The company also regained exclusive Canadian distribution rights for TULSA-PRO, positioning it to capitalize on untapped domestic demand despite current provincial insurance gaps.

To drive further growth, Profound is deploying a direct sales team across North America and partnering with select distributors internationally to broaden patient access. These strategic moves aim to accelerate global commercialization of the TULSA-PRO system and bolster market penetration outside its initial Canadian installation.